ÖZET
Renal transplantasyon, renal yetmezlikli hastalar için yaşam kalitesini belirgin şekilde artıran önemli bir tedavi seçeneğidir. Transplantasyon sonrası hastalara verilen immünosupresif ilaçlar, organ rejeksiyonunu önlemek için vazgeçilmezdir ve transplantasyon başarısında önemli role sahiptirler. Ancak, bu ilaçların paternal maruziyetinin erkek fertilitesi üzerinde olası olumsuz etkileri hakkında bilgiler sınırlıdır. Bunun yanında yapılan gözlemsel çalışmalar, teratojenite riskinde sadece maternal ilaç maruziyetinin değil, aynı zamanda paternal ilaç maruziyetinin de rol oynayabileceğini desteklemektedir. Bu durum, bebek sahibi olmayı planlayan kronik ilaç kullanan erkeklerde tedavi yönetiminde güçlüklere yol açmaktadır. Makale, renal transplant hastalarında kullanılan immünosupresif ilaçların paternal teratojenite ve fertilite üzerine etkilerini değerlendirerek, klinisyenlerin bu konudaki farkındalığını artırmayı hedeflemektedir. Bu ilaçların uzun dönem etkilerini anlamak için daha kapsamlı çalışmalara ihtiyaç duyulmakla birlikte çocuk sahibi olmayı planlayan ve immünosupresif tedavi alması planlanan hastalarda, sperm bankacılığı gibi seçeneklerin de göz önünde bulundurulması önerilmektedir.
References
1
Chandra A, Midtvedt K, Åsberg A, Eide IA. Immunosuppression and Reproductive Health After Kidney Transplantation. Transplantation 2019;103:e325-33.
2
Çeliker A, Göçer M. Türkiye’de ve Dünyada Teratojenite Bilgi Servislerinin Çalışma Koşulları ve Sağladıkları Hizmetler. Hacettepe University Journal of the Faculty of Pharmacy 2021;41:102-16.
3
Uysal N. Paternal Metotreksat Maruziyeti Sonrası Gebelik Sonuçları: Sistematik Derleme Ve Meta-Analiz (tez). Izmir Katip Celebi Univ 2022.
4
Bermas BL. Paternal safety of anti-rheumatic medications. Best Pract Res Clin Obstet Gynaecol 2020;64:77-84.
5
Perez-Garcia LF, Dolhain RJEM, Vorstenbosch S, Bramer W, van Puijenbroek E, Hazes JMW, et al. The effect of paternal exposure to immunosuppressive drugs on sexual function, reproductive hormones, fertility, pregnancy and offspring outcomes: a systematic review. Hum Reprod Update 2020;26:961-1001.
6
Reprotox ® Website Copyright© 1994-2023 [Internet]. [cited 2023 Nov 24]. Available from: https://www.reprotox.org/member
7
Kantarci G, Sahin S, Uras AR, Ergin H. Effects of different calcineurin inhibitors on sex hormone levels in transplanted male patients. Transplant Proc 2004;36:178-9.
8
Haberman J, Karwa G, Greenstein SM, Soberman R, Glicklich D, Tellis V, et al. Male fertility in cyclosporine-treated renal transplant patients. J Urol 1991;145:294-6.
9
Georgiou GK, Dounousi E, Harissis HV. Calcineurin inhibitors and male fertility after renal transplantation - a review. Andrologia 2016;48:483-90.
10
Zakhem GA, Goldberg JE, Motosko CC, Cohen BE, Ho RS. Sexual dysfunction in men taking systemic dermatologic medication: A systematic review. J Am Acad Dermatol 2019;81:163-72.
11
Boyer A, Lobbedez T, Ouethrani M, Thuillier Lecouf A, Bouvier N, Châtelet V, et al. Paternity in male kidney transplant recipients: a French national survey, the PATeRNAL study. BMC Nephrol 2020;21:483.
12
Mouyis M, Flint JD, Giles IP. Safety of anti-rheumatic drugs in men trying to conceive: A systematic review and analysis of published evidence. Semin Arthritis Rheum 2019;48:911-20.
13
Tai J, Tze WJ, Murase N, Starzl TE. Effect of FK506 on rat Leydig cell function--in vivo and in vitro study. Metabolism 1994;43:533-7.
14
Flint J, Panchal S, Hurrell A, van de Venne M, Gayed M, Schreiber K, et al. BSR and BHPR guideline on prescribing drugs in pregnancy and breastfeeding-Part I: standard and biologic disease modifying anti-rheumatic drugs and corticosteroids. Rheumatology (Oxford) 2016;55:1693-7.
15
Accord Healthcare Inc. 2020. Mycophenolate mofetil product labeling. [Internet]. Available from: https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=741e079a-646b-47ec-84ac-8e12574c2aaf&type=display
16
Sammaritano LR, Bermas BL, Chakravarty EE, Chambers C, Clowse MEB, Lockshin MD, et al. 2020 American College of Rheumatology Guideline for the Management of Reproductive Health in Rheumatic and Musculoskeletal Diseases. Arthritis Rheumatol 2020;72:529-56.
17
Midtvedt K, Bergan S, Reisæter AV, Vikse BE, Åsberg A. Exposure to Mycophenolate and Fatherhood. Transplantation 2017;101:e214-7.
18
Dejaco C, Mittermaier C, Reinisch W, Gasche C, Waldhoer T, Strohmer H, et al. Azathioprine treatment and male fertility in inflammatory bowel disease. Gastroenterology 2001;121:1048-53.
19
Xu L, Han S, Liu Y, Wang H, Yang Y, Qiu F, et al. The influence of immunosuppressants on the fertility of males who undergo renal transplantation and on the immune function of their offspring. Transpl Immunol 2009;22:28-31.
20
Nørgård B, Pedersen L, Jacobsen J, Rasmussen SN, Sørensen HT. The risk of congenital abnormalities in children fathered by men treated with azathioprine or mercaptopurine before conception. Aliment Pharmacol Ther 2004;19:679-85.
21
Hoeltzenbein M, Weber-Schoendorfer C, Borisch C, Allignol A, Meister R, Schaefer C. Pregnancy outcome after paternal exposure to azathioprine/6-mercaptopurine. Reprod Toxicol 2012;34:364-9.
22
Shim L, Eslick GD, Simring AA, Murray H, Weltman MD. The effects of azathioprine on birth outcomes in women with inflammatory bowel disease (IBD). J Crohns Colitis 2011;5:234-8.
23
Friedman S, Larsen MD, Magnussen B, Jølving LR, de Silva P, Nørgård BM. Paternal use of azathioprine/6-mercaptopurine or methotrexate within 3 months before conception and long-term health outcomes in the offspring-A nationwide cohort study. Reprod Toxicol 2017;73:196-200.
24
Viktil KK, Engeland A, Furu K. Outcomes after anti-rheumatic drug use before and during pregnancy: a cohort study among 150,000 pregnant women and expectant fathers. Scand J Rheumatol 2012;41:196-201.
25
Zydus Pharmaceuticals Inc. 2023. Sirolimus prescribing information [Internet]. Available from: https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=ec473170-47f1-4a5c-b4d9-ac36406ed241&type=display
26
Chen Y, Zhang Z, Lin Y, Lin H, Li M, Nie P, et al. Long-term impact of immunosuppressants at therapeutic doses on male reproductive system in unilateral nephrectomized rats: a comparative study. Biomed Res Int 2013;2013:690382.
27
Rovira J, Diekmann F, Ramírez-Bajo MJ, Bañón-Maneus E, Moya-Rull D, Campistol JM. Sirolimus-associated testicular toxicity: detrimental but reversible. Transplantation 2012;93:874-9.
28
Krämer BK, Neumayer HH, Stahl R, Pietrzyk M, Krüger B, Pfalzer B, et al. Graft function, cardiovascular risk factors, and sex hormones in renal transplant recipients on an immunosuppressive regimen of everolimus, reduced dose of cyclosporine, and basiliximab. Transplant Proc 2005;37:1601-4.
29
Wetzstein M, Weestel PF, Choukroun G. Évérolimus et azoospermie, un lien de cause à effet ? À propos d’un cas chez un patient greffé rénal. Nephrol Ther 2014;10:44-5.
30
Uptodate 2023 [Internet]. [cited 2023 Dec 4]. Available from: https://www.uptodate.com/contents/search
31
Gold R, Stefoski D, Selmaj K, Havrdova E, Hurst C, Holman J, et al. Pregnancy Experience: Nonclinical Studies and Pregnancy Outcomes in the Daclizumab Clinical Study Program. Neurol Ther 2016;5:169-82.
32
Mahmud N, Klipa D, Ahsan N. Antibody immunosuppressive therapy in solid-organ transplant: Part I. MAbs 2010;2:148-56.
33
EMA. 2022. Lemtrada. Summary of Product Characteristics [Internet]. [cited 2023 Dec 26]. Available from: https://www.ema.europa.eu/documents/product-information/lemtrada-epar-product-information_en.pdf
34
Hamdi SM, Walschaerts M, Bujan L, Rostaing L, Kamar N. A prospective study in male recipients of kidney transplantation reveals divergent patterns for inhibin B and testosterone secretions. Basic Clin Androl 2014;24:11.
